Finally, Pelzl et al. also found that antibody‐mediated procoagulant platelet formation in COVID‐19 is AKT dependent, suggesting that targeting this pathway might represent a promising strategy to reduce the risk for thrombosis in patients with severe COVID-19 [119] (Supplementary Table 1). The gene discussed is AKT1; the disease is COVID-19.